about
Impaired Hepatitis C Virus-Specific T Cell Responses and Recurrent Hepatitis C Virus in HIV CoinfectionImmunologic evidence for lack of heterologous protection following resolution of HCV in patients with non genotype 1 infectionEarly Interferon Therapy for Hepatitis C Virus Infection Rescues Polyfunctional, Long-Lived CD8+ Memory T CellsFactors associated with spontaneous clearance of hepatitis C virus among illicit drug usersHepatitis C Virus (HCV)–Specific Immune Responses of Long‐Term Injection Drug Users Frequently Exposed to HCVThe impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population studyCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersCandidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunitiesAn update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.Protective immunity against hepatitis C: many shades of gray.Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users.Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.Factors associated with spontaneous clearance of hepatitis C virus in Chinese populationHepatitis C virus-specific T-cell immune responses in seronegative injection drug usersStrong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responsesSpontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlatesAssessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series reportCoinfection with HIV-1 and HCV--a one-two punch.Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzeesReplication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infectionThe more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.HCV-HIV coinfection: simple messages from a complex disease.Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 StudyHepatitis C virus in American Indian/Alaskan Native and Aboriginal peoples of North America.Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfectionHepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccineDoes psychological status influence clinical outcomes in patients with inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: an observational cohort prospective studyAntiviral therapy: chronic hepatitis C.Hepatitis C virus vaccines among people who inject drugs.Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centreCIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentCurrent approaches to HCV infection in current and former injection drug users.Prisons and HCV: a review and a report on an experience in New South Wales Australia.High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.
P2860
Q27477797-9F861F2D-DF1A-429F-B545-6B32B03E282BQ27481055-DF54ADF7-1293-46A1-9319-0174D8B34A2CQ27487038-111345C6-6EF4-4E86-9DA0-8AA84F765D31Q27488233-17DD6736-302C-4D89-860F-95AD6A7378C6Q27488816-BDD725B2-2EF3-425B-8C1E-D2455346F5DAQ28476680-FFE0D063-2E9E-447F-9DB2-4FA109B6ED7EQ28483820-2B59E2D8-FA2F-4583-A9C8-748B58A4861DQ30226978-22A08B41-2CB4-41B0-91E2-3DF2413C09AAQ30453975-FB69DE95-14DD-4E89-A7B6-C76C6FAF5402Q30884457-106C7B64-E7AA-48D2-BD1F-A8A65BA3D2A3Q33759224-0690C513-909B-42EC-BCA0-5EA6135C9CECQ33824723-DD2EA532-F186-425C-97AB-618C3740B80BQ33929089-66F1D328-06A1-46C0-9178-79EA754B1672Q34009690-5FC4F464-BD6D-4519-A08F-A4C7A9B06AB2Q34381567-9C66EF83-F96E-4C2A-B0C2-4007515B8399Q34449537-1698277E-92AB-402F-9E52-1E30C9CCA2E7Q34455275-45FB891A-6A30-4ECB-892B-680EC80D7524Q34604833-CC57E5C8-BF9A-40BD-880A-2BD641B17365Q35118973-28044D97-1876-4C1A-B6B5-3365F2D1A69DQ35137038-1979226B-EC9A-489D-9A18-A8712A04B88CQ35249069-89865A83-D232-46E5-BEE8-9CB268009F48Q35793834-11626DB8-17C0-4455-8DE8-C68DF89F263AQ35846408-0C392E0A-232D-4B98-952B-D754001AA089Q35883439-529ABABD-725C-47ED-A97D-5A05ABBA18A4Q36026387-6A5F2D65-3858-4A51-97E7-58E7F4B2E46BQ36148971-55A7B83A-4AE2-4BD1-847B-8DBE98CEB043Q36482820-A60CD99B-93DA-4200-AF7D-9A8637C94BDBQ36517794-3A7BC7DB-9821-4E09-932C-98E36C7CCE21Q36607811-8EA9A2F5-8166-450B-847B-EA3C6D9E92CDQ36717008-1AFD8B24-0E75-4E81-8129-9A74BDD69528Q36743391-9CF4B8F3-A2D8-4B1E-B8A2-32C672614A27Q36980750-0547BB03-A3E9-4836-9237-D311CED404DEQ37042440-873744B6-C7C0-4239-89C1-17FC2B2BF021Q37092648-C24BDFD6-3CDF-41ED-8AFA-F75AAE9A1DFDQ37100669-CE50BD4E-3528-45F8-94C1-B86D179EB204Q37235530-CBDFE255-1F95-4460-A968-F112086AAF00Q37242489-510A6A48-1D4F-412A-8E09-DAAF6835730DQ37288631-2347B8CE-36D4-4337-87BC-34E3D2036F42Q37460833-EBA65AE6-B8DF-4163-A9BF-43ECA52F71FAQ37525649-C9332940-8C9A-4245-B68B-D238E31C5ECF
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Hepatitis C virus reinfection in injection drug users.
@en
Hepatitis C virus reinfection in injection drug users.
@nl
type
label
Hepatitis C virus reinfection in injection drug users.
@en
Hepatitis C virus reinfection in injection drug users.
@nl
prefLabel
Hepatitis C virus reinfection in injection drug users.
@en
Hepatitis C virus reinfection in injection drug users.
@nl
P2093
P356
P1433
P1476
Hepatitis C virus reinfection in injection drug users.
@en
P2093
Brian Conway
Calvin Lai
Jason Grebely
Jesse D Raffa
Mark W Tyndall
P304
P356
10.1002/HEP.21376
P407
P50
P577
2006-11-01T00:00:00Z